Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject
- First Posted Date
- 2010-11-07
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01236105
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT01234402
- Locations
- 🇨🇦
ImClone Investigational Site, Toronto, Ontario, Canada
A Study in Non-Small Cell Lung Cancer
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 172
- Registration Number
- NCT01232452
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey
A Study of Brain Receptor Occupancy in Healthy Subjects
- Conditions
- Alcohol Dependence
- Interventions
- Drug: opioid receptor kappa antagonist
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2011-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT01232439
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States
A Safety Study of LY2886721 Multiple Doses in Healthy Subjects
- First Posted Date
- 2010-10-25
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01227252
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glendale, California, United States
A Study in Pediatric Participants With Generalized Anxiety Disorder
- Conditions
- Anxiety NeurosesNeuroses, AnxietyAnxiety States, Neurotic
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2014-03-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 281
- Registration Number
- NCT01226511
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa
A Study in Advanced Cancer
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 84
- Registration Number
- NCT01226485
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 75
- Registration Number
- NCT01220271
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1117
- Registration Number
- NCT01215955
- Locations
- 🇿🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Somerset West, South Africa
A Phase 1 Study in Patients With Solid Tumors
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01215916
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Brunswick, New Jersey, United States